PICOGEN: five years experience with a genetic counselling program for dementia
J Fortea1, A Lladó, J Clarimón
1Unidad de Alzheimer y otros trastornos cognitivos, Hospital Clínic de Barcelona, Barcelona, Spain.
Introduction:
We describe the 5 year experience of a genetic counselling program for familial dementias (the PICOGEN program).
Methods:
The neurologist selected the candidates for genetic testing in the screening visit based on family history and phenotype (Alzheimer disease-AD, frontotemporal lobar degeneration-FTLD, or prion disease). Asymptomatic subjects who decided to know their genetic status were evaluated within a structured protocol by the psychiatrist and psychologist prior to entering the program and followed up afterwards.
Results:
A total of 87 patients from 72 families were candidates for the genetic study, 20 of the 72 families had a family history of autosomal dominant early-onset dementia (ADEOD). A pathogenic mutation was found in 22 patients (8 PSEN1, 1 PSEN2, 1 APP, 4 MAPT, 8 PRNP), 5 of which had not been previously described. All positive cases, except for 1 PSEN1 (12.5%) and 4 PRNP (50%) showed ADEOD. In 3 ADEOD cases (15%) no pathogenic mutation was found. After individual genetic counselling, 24/54 asymptomatic subjects at risk decided to have the pre-symptomatic study, of whom 10 (42%) were carriers of the pathogenic mutation. In the follow up, no major psychiatric complication was observed.
Conclusions:
In our series, family history of ADEOD was a sensitive criterion for the detection of pathogenic mutations in AD and FTLD but not in prion diseases. No genetic anomalies were detected in 15% of the ADEOD cases using conventional diagnostic procedures, and 43% of pre-symptomatic subjects at risk who received individual genetic counselling decided to have the study. The pre-symptomatic diagnosis proved to be safe under these conditions.
More Related Videos
Related Concept Videos
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Alzheimer Disease l: Introduction
Dementia l: Introduction
Huntington Disease l: Introduction
Intellectual Disability
Pharmacogenetics and Pharmacogenomics: Overview


